Cargando…

Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME

AIMS: The EMPA‐REG OUTCOME trial demonstrated reductions in cardiovascular (CV) death and heart failure (HF) outcomes with empagliflozin, a sodium–glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes and established CV disease over a study period of 3 years. We aimed to investigate t...

Descripción completa

Detalles Bibliográficos
Autores principales: Pellicori, Pierpaolo, Ofstad, Anne Pernille, Fitchett, David, Zeller, Cordula, Wanner, Christoph, George, Jyothis, Zinman, Bernard, Brueckmann, Martina, Lindenfeld, JoAnn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754994/
https://www.ncbi.nlm.nih.gov/pubmed/32915523
http://dx.doi.org/10.1002/ehf2.12891
_version_ 1783626286693875712
author Pellicori, Pierpaolo
Ofstad, Anne Pernille
Fitchett, David
Zeller, Cordula
Wanner, Christoph
George, Jyothis
Zinman, Bernard
Brueckmann, Martina
Lindenfeld, JoAnn
author_facet Pellicori, Pierpaolo
Ofstad, Anne Pernille
Fitchett, David
Zeller, Cordula
Wanner, Christoph
George, Jyothis
Zinman, Bernard
Brueckmann, Martina
Lindenfeld, JoAnn
author_sort Pellicori, Pierpaolo
collection PubMed
description AIMS: The EMPA‐REG OUTCOME trial demonstrated reductions in cardiovascular (CV) death and heart failure (HF) outcomes with empagliflozin, a sodium–glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes and established CV disease over a study period of 3 years. We aimed to investigate the early benefit–risk profile of empagliflozin in patients enrolled in the EMPA‐REG OUTCOME trial according to HF status at baseline. METHODS AND RESULTS: The effects of treatments on glycated haemoglobin, systolic blood pressure and body weight, and on the HF endpoints of hospitalization for HF (HHF), HHF or CV death, and HHF or all‐cause mortality were evaluated at 12 weeks, 6 months, and 1 year after randomization. Occurrence of adverse events (AEs) during these time points was also evaluated. Compared with placebo, empagliflozin lowered glycated haemoglobin, systolic blood pressure, and body weight and rates of all the HF endpoints, as early as at 12 weeks, regardless of HF status at baseline. Favourable clinical and metabolic effects were maintained over time. AEs were generally higher in those with HF than without HF; however, compared with placebo, empagliflozin did not increase risk of developing AEs over the first year of treatment. CONCLUSIONS: In the EMPA‐REG OUTCOME trial, the use of empagliflozin led to early and beneficial effects on clinical, metabolic, and HF outcomes in patients with type 2 diabetes with or without HF at baseline, which were already apparent within 12 weeks from initiation of treatment. Over the first year of treatment, no safety concern was detected with the use of empagliflozin.
format Online
Article
Text
id pubmed-7754994
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77549942020-12-23 Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME Pellicori, Pierpaolo Ofstad, Anne Pernille Fitchett, David Zeller, Cordula Wanner, Christoph George, Jyothis Zinman, Bernard Brueckmann, Martina Lindenfeld, JoAnn ESC Heart Fail Short Communications AIMS: The EMPA‐REG OUTCOME trial demonstrated reductions in cardiovascular (CV) death and heart failure (HF) outcomes with empagliflozin, a sodium–glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes and established CV disease over a study period of 3 years. We aimed to investigate the early benefit–risk profile of empagliflozin in patients enrolled in the EMPA‐REG OUTCOME trial according to HF status at baseline. METHODS AND RESULTS: The effects of treatments on glycated haemoglobin, systolic blood pressure and body weight, and on the HF endpoints of hospitalization for HF (HHF), HHF or CV death, and HHF or all‐cause mortality were evaluated at 12 weeks, 6 months, and 1 year after randomization. Occurrence of adverse events (AEs) during these time points was also evaluated. Compared with placebo, empagliflozin lowered glycated haemoglobin, systolic blood pressure, and body weight and rates of all the HF endpoints, as early as at 12 weeks, regardless of HF status at baseline. Favourable clinical and metabolic effects were maintained over time. AEs were generally higher in those with HF than without HF; however, compared with placebo, empagliflozin did not increase risk of developing AEs over the first year of treatment. CONCLUSIONS: In the EMPA‐REG OUTCOME trial, the use of empagliflozin led to early and beneficial effects on clinical, metabolic, and HF outcomes in patients with type 2 diabetes with or without HF at baseline, which were already apparent within 12 weeks from initiation of treatment. Over the first year of treatment, no safety concern was detected with the use of empagliflozin. John Wiley and Sons Inc. 2020-09-11 /pmc/articles/PMC7754994/ /pubmed/32915523 http://dx.doi.org/10.1002/ehf2.12891 Text en © 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Short Communications
Pellicori, Pierpaolo
Ofstad, Anne Pernille
Fitchett, David
Zeller, Cordula
Wanner, Christoph
George, Jyothis
Zinman, Bernard
Brueckmann, Martina
Lindenfeld, JoAnn
Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
title Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
title_full Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
title_fullStr Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
title_full_unstemmed Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
title_short Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
title_sort early benefits of empagliflozin in patients with or without heart failure: findings from empa‐reg outcome
topic Short Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754994/
https://www.ncbi.nlm.nih.gov/pubmed/32915523
http://dx.doi.org/10.1002/ehf2.12891
work_keys_str_mv AT pellicoripierpaolo earlybenefitsofempagliflozininpatientswithorwithoutheartfailurefindingsfromemparegoutcome
AT ofstadannepernille earlybenefitsofempagliflozininpatientswithorwithoutheartfailurefindingsfromemparegoutcome
AT fitchettdavid earlybenefitsofempagliflozininpatientswithorwithoutheartfailurefindingsfromemparegoutcome
AT zellercordula earlybenefitsofempagliflozininpatientswithorwithoutheartfailurefindingsfromemparegoutcome
AT wannerchristoph earlybenefitsofempagliflozininpatientswithorwithoutheartfailurefindingsfromemparegoutcome
AT georgejyothis earlybenefitsofempagliflozininpatientswithorwithoutheartfailurefindingsfromemparegoutcome
AT zinmanbernard earlybenefitsofempagliflozininpatientswithorwithoutheartfailurefindingsfromemparegoutcome
AT brueckmannmartina earlybenefitsofempagliflozininpatientswithorwithoutheartfailurefindingsfromemparegoutcome
AT lindenfeldjoann earlybenefitsofempagliflozininpatientswithorwithoutheartfailurefindingsfromemparegoutcome